Overview

Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

Status:
Terminated
Trial end date:
2017-11-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the MTD, Pharmacokinetics and preliminary efficacy of T0001 in Rheumatoid Arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Treatments:
Etanercept
Immunoglobulin Fc Fragments
T0001